Personalised medicine (also referred to as precision medicine) is an evolving field of medicine in which treatments are selected based on the detection of disease markers in individual patients.

This enables doctors to prescribe treatment regimens that are tailored to individual patients’ medical needs. Personalised medicine is not only used in treatment of diseases, but also has great potential for disease prevention, early detection, accurate diagnosis and long-term management. This rapidly growing field is seeing many advancements in cancer treatment and targeted drug delivery. Despite the sometimes-unique nature of each item that will be produced, many companies working in this field have found ways to leverage intellectual property to protect their technological developments, secure investment and commercialise their products.

This session will cover:

  • an overview of personalised medicine including the use of companion diagnostics (CDx) to select patient-specific drugs and examples of personalised medical devices
  • an overview of UK and European patent law relating to patentability of biotechnology inventions and methods of treatment relevant to personalised medicine inventions, and
  • case studies identifying considerations for developing IP strategies to support the commercialisation of a personalised medicine or a personalised medical device.

Presenters:

Dr Laurence Gainey and Dr Adam Hines

You may also like

Motivating big pharma to embrace emerging technology: it’s not always about the small molecule

Tuesday 2nd March

The discussion will look at the advantages and disadvantages of engaging with Big Pharma, and then look at what can attract Big Pharma to new territories. Our conclusions will be used to reflect broadly on what this may mean for the microbiome field.

The power of bioinformatics: a focus on capturing bioinformatics innovation as part of an IP strategy

Thursday 18th March

We will look at patent trends in bioinformatics along with some real life case studies in order to see how companies have successfully protected bioinformatics innovations in areas including computational neuroscience, DNA Sequencing and remote healthcare monitoring.

Careful crafting and compliant claims; Advertising Standards Authority regulation in the health sector

23rd February

This session will examine the provisions of the Advertising Standards Authority codes which relate to the health sector. We will consider a number of recent decisions in this area and offer practical advice on how to ensure advertising for those operating in the healthcare sector is compliant with the ASA’s codes.